Oncology Venture Up-date
Hoersholm, Denmark; August 25, 2016 – Oncology Venture Sweden AB (OV:ST) up-dates information about its drug candidates APO010, Irofulven and LiPlaCis in the pipeline and informs about potential drugs in a US Special Purpose Vehicle (SPV) focusing on Women’s Cancers using the Drug Response Predictor -DRP- to select high likely responding patients. At the IPO in July 2015 Oncology Venture set out to in-license and evaluate 5 products in a three-year period. OV has already now in-licensed and started development on three of these and is on an overall schedule ahead of its initial timelines.